00:59 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 on Nov. 30 after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate...
23:45 , Nov 30, 2018 |  BC Extra  |  Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 Friday after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate says would...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
19:13 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Cell culture and mouse studies suggest adoptive transfer of IL-15-cultured T cells could help treat B7-H6 tumor cell ligand-positive cancers. CD8 + T cells derived from human donor blood and cultured for...
23:50 , Jun 18, 2018 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
18:30 , May 11, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse...